1. SOFT TISSUE SARCOMA DelveInsight’s launched a new report on “Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2030”. The report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Soft Tissue Sarcoma (STS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The Soft Tissue Sarcoma market report provides analysis regarding current treatment practices, emerging drugs like AL3818, Fibromun, AL3818, Ripretinib, market share of the individual therapies, historical, current and forecasted Soft Tissue Sarcoma market Size from 2017 to 2030 segmented by seven major markets. Soft Tissue Sarcoma Soft Tissue Sarcoma Overview Soft-tissue sarcoma are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels, and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease’s clinical course. According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease, but the affected individuals may notice slow-growing, painless mass in the affected area. Soft Tissue Sarcoma Treatment This chapter covers the details of conventional and current medical therapies available in the Soft tissue sarcoma market for the treatment of the condition. It also provides the country-wise Soft Tissue Sarcoma treatment guidelines and algorithm across the United States, Europe and Japan. DelveInsight’s Soft tissue sarcoma market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Soft tissue sarcoma treatment algorithms and treatment guidelines in the US, Europe, and Japan. Soft Tissue Sarcoma Epidemiology Soft Tissue Sarcoma has various subtypes. It was observed that in the United States and European countries, liposarcoma and leiomyosarcoma were the most incident subtypes of STS, which contributed to the majority of the cases. Whereas in Japan, subtypes, fibroblastic sarcomas and liposarcoma were more common. According to DelveInsight’s, the total Soft Tissue Sarcoma incident population in seven major markets was 40,155 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounts for the highest number of Soft Tissue Sarcoma cases. In 2017, there were 12,390 incident cases of STS—which did not include GIST cases—in the United States. The total incident cases of GIST which were observed in the United States in 2017 accounted for 5,090. This lead to the total Soft Tissue Sarcoma incident population to 17,480 in 2017.

2. Soft Tissue Sarcoma Drug Chapters Drug chapter segment of the Soft Tissue Sarcoma report encloses the detailed analysis of Soft Tissue Sarcoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Soft Tissue Sarcoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The report provides the details of the emerging therapies under the late and mid-stage of development for Soft Tissue Sarcoma treatment and marketed product available for Soft Tissue Sarcoma treatment. STS primarily encountered in adults but can affect patients of any age. There are many histologic subtypes, and the malignancy can be low or high grade. Soft tissue sarcoma treatments may include surgery, chemotherapy, radiation therapy, or a combination of these therapies. The emerging therapies are classified into four categories based on their line of therapy. The upcoming first-line therapies that are going to be launched in the forecasted period includes, AL3818 (anlotinib) and Fibromun. The second-line emerging therapies include Vigil in combination with irinotecan and temozolomide, AL3818, GSK 3377794, Ripretinib (DCC-2618), Tazemetostat, Abemaciclib, Pembrolizumab, Crizotinib, ABI-009, and SRA737. The third-line emerging therapies include Avapritinib, Cabozantinib, and Selinexor. The fourth-line emerging therapies include Avapritinib, TAS-116, Crenolanib, and Ripretinib. Soft Tissue Sarcoma Market Outlook The Soft Tissue Sarcoma market size is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounts for the highest Soft Tissue Sarcoma market size. Among EU5, Germany had the highest Soft Tissue Sarcoma market size in 2017 USD 22.06 million, followed by Italy. The market size of STS (excluding GIST) in Japan was found to be least in 2017. The key companies involved for Soft Tissue Sarcoma market treatment are Amgen, BioPharma, AstraZeneca and many others. Soft Tissue Sarcoma Drugs Uptake The current Soft Tissue Sarcoma market size is mainly attributed to Votrient, Yondelis, Halaven, and various anthracycline and non-anthracycline regimens. The market size of GIST in the United States was found to be USD 119.7 million in 2017and expected to increase during the forecast period (2020–2030)due to potential therapies Vitrakvi, Rozlytrek, Avapritinib, Ripretinib and others. View full report @https://www.delveinsight.com/report-store/soft-tissue- sarcoma-market Frequently asked questions: At what CAGR, Soft Tissue Sarcoma market is expected to grow for the study period 2017- 30? The Soft Tissue Sarcoma market is expected to increase at a CAGR of 6.47% during forecast period (2017-2030). Which geography accounted for the largest Soft Tissue Sarcoma market size? United States accounted for the largest Soft Tissue Sarcoma market size. What is forecasted soft tissue sarcoma market size in 2030? DelveInsight estimates an increase in STS Market Size during the study period, 2017–2030

3. What are the present Soft Tissue Sarcoma market drivers? Competitive Landscape, Precision Medicine Approach & Novel Therapies for Subtype of STS. What are the Soft Tissue Sarcoma market barriers? High Cost of Treatment, Stringent Government Regulations & High Failure Rate in the Clinical Trials. How many companies are developing drugs for soft tissue sarcoma? Currently more than 8 companies are developing drugs for soft tissue sarcoma. Which are the leading companies in soft tissue sarcoma market? Key Companies - Bayer, Gradalis, Karyopharm, Novartis, Eli Lilly, GlaxoSmithKline, Merck Sharp& Dohme Corp. and several others. How is epidemiology segmented for soft tissue sarcoma? Total Incident Cases of STS in the 7MM, Gender-Specific Incidence of STS in the 7MM, Gender- Specific Incidence of STS in the 7MM, Incidence of STS by Extremities (%) in the 7MM, Stage- Specific Incidence of STS in the 7MM and Age-Specific Incidence of STS in the 7MM. Request for free sample pages: https://www.delveinsight.com/sample- request/soft-tissue-sarcoma-market